Clinical trial · Observational
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma
Relationship Between Histopathological Features, Mutation Status, 18F-FDG PET/CT Radiomic Imaging Parameters as Well as Clinical Outcome in Patients With Treatment-naïve Non-small Cell Lung Cancer
NCT04276025CI-TRIAL-00043510PANUcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Retrospective study in patients with therapy-naive non small cell lung carcinoma correlating presurgical F18-FDG-PET/CT imaging texture analysis data with postsurgical molecular pathology data and clinical patient outcome. Main aim is to identify pretherapeutic prognostic factors.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| NSCLC | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Clinical routine F18-FDG-PET/CT, molecular pathology and clinical outcome | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- label
- German cohort Bayreuth
- description
- Retrospective analysis of clinical routine F18-FDG-PET/CT, molecular pathology and clinical outcome data.
- interventionNames
- Other: Clinical routine F18-FDG-PET/CT, molecular pathology and clinical outcome
- label
- German cohort Hof
- description
- Retrospective analysis of clinical routine F18-FDG-PET/CT, molecular pathology and clinical outcome data.
- interventionNames
- Other: Clinical routine F18-FDG-PET/CT, molecular pathology and clinical outcome
- label
- Chinese cohort Beijing
- description
- Retrospective analysis of clinical routine F18-FDG-PET/CT, molecular pathology and clinical outcome data.
- interventionNames
- Other: Clinical routine F18-FDG-PET/CT, molecular pathology and clinical outcome
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Retrospective selection of both German cohort NSCLC patients with concomitant gene mutation results, CTCs accounting results and 18F-FDG PET/CT imaging data before lung tumor surgery (both German patient cohorts) * Retrsopective selection of Chinese NSCLC patients with concomitant gene mutation results, CTCs accounting results and 18F-FDG PET/CT imaging data before lung tumor surgery (Chinese patient collective) Exclusion Criteria: * NSCLC patients with surgical resection of the target/primary tumor before 18F-FDG PET/CT scanning. * NSCLC patients with elevated blood glucose levels (\> 150 mg/dl) immediately before 18F-FDG injection. * based on PET CT scanning no concomitant malignancies
References
Publications (27)
- BACKGROUNDZhu QG, Zhang SM, Ding XX, He B, Zhang HQ. Driver genes in non-small cell lung cancer: Characteristics, detection methods, and targeted therapies. Oncotarget. 2017 Apr 10;8(34):57680-57692. doi: 10.18632/oncotarget.17016. eCollection 2017 Aug 22. PMID 28915704
- BACKGROUNDO'Flaherty L, Wikman H, Pantel K. Biology and clinical significance of circulating tumor cell subpopulations in lung cancer. Transl Lung Cancer Res. 2017 Aug;6(4):431-443. doi: 10.21037/tlcr.2017.07.03. PMID 28904887
- BACKGROUNDSollini M, Cozzi L, Antunovic L, Chiti A, Kirienko M. PET Radiomics in NSCLC: state of the art and a proposal for harmonization of methodology. Sci Rep. 2017 Mar 23;7(1):358. doi: 10.1038/s41598-017-00426-y. PMID 28336974
- BACKGROUNDVillalobos P, Wistuba II. Lung Cancer Biomarkers. Hematol Oncol Clin North Am. 2017 Feb;31(1):13-29. doi: 10.1016/j.hoc.2016.08.006. PMID 27912828
- BACKGROUNDKhalil FK, Altiok S. Advances in EGFR as a Predictive Marker in Lung Adenocarcinoma. Cancer Control. 2015 Apr;22(2):193-9. doi: 10.1177/107327481502200210. PMID 26068764
- BACKGROUNDSholl LM. Biomarkers in lung adenocarcinoma: a decade of progress. Arch Pathol Lab Med. 2015 Apr;139(4):469-80. doi: 10.5858/arpa.2014-0128-RA. Epub 2014 Sep 25. PMID 25255293
- BACKGROUNDSharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer. 2007 Mar;7(3):169-81. doi: 10.1038/nrc2088. PMID 17318210
- BACKGROUNDCardarella S, Ogino A, Nishino M, Butaney M, Shen J, Lydon C, Yeap BY, Sholl LM, Johnson BE, Janne PA. Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer. Clin Cancer Res. 2013 Aug 15;19(16):4532-40. doi: 10.1158/1078-0432.CCR-13-0657. Epub 2013 Jul 5.